Extended Data Table 2 Pharmacokinetic parameters of JNJ-1802 in mice (a, b) and monkeys (rhesus macaques) (a, c) after intravenous (a) and oral dosing (b-c)

From: Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates

  1. aData are from female and male rhesus macaques (Biomedical Primate Research Center). bData are from male rhesus macaques (Walter Reed Army Institute of Research). JNJ-1802 was administered as a single dose to male CD-1 mice (6–8 weeks old) intravenously (a) as a solution formulated in PEG400/water (7:3) at 2.5 mg/kg or via oral gavage (b) as a solution formulated in PEG400/water (8:2) at 1, 3, 10 or 30 mg/kg. Values represent mean ± standard deviation (s.d) from 3 animals. F was calculated using AUC(0-24h). JNJ-1802 was administered to female/male monkeys (adult) intravenously (a) as a solution formulated in PEG400/water (7:3) at 1.0 mg/kg or via oral gavage (c) for 12 or 14 days as a solution formulated in PEG400 at 0.01, 0.18, or 3 and 6 mg/kg. Values represent mean ± s.d. from 3 animals. CLp, plasma clearance; Vdssp, Volume of distribution in plasma at steady state; t1/2, terminal phase elimination half-life; AUC, area under the plasma concentration versus time curve; AUC(0-24h), AUC up to 24h; AUC(0-inf), AUC curve to infinite time; Cmax, maximum plasma concentration; tmax, the time to reach Cmax; F, bioavailability; PEG400, polyethylene glycol 400.
  2. Source Data
Back to article page